 REDWOOD CITY, Calif., April 07, 2022 GLOBE NEWSWIRE -- Bolt Biotherapeutics Nasdaq: BOLT, a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022, at 12:45 p.m. PT 3:45 p.m. ET. 